{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:28:21Z","timestamp":1787801301418,"version":"build-2784847793"},"reference-count":23,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2020,9,30]]},"abstract":"<jats:p>The adrenal glands produce significant amounts of steroid hormones and their metabolites, with various levels of androgenic activities. Until recently, the androgenic potency of these adrenal-derived compounds were not well known, but some recent studies have shown that the production of 11-oxo- and 11\u03b2-hydroxy-derived testosterone and dihydrotestosterone evidently have high androgenic activity. This fact has clinical importance, for instance, in various types of congenital adrenal hyperplasia with androgenization or polycystic ovarian syndrome, and laboratory determinations of these substances could help to better evaluate the total androgen pressure in patients with these disorders. Another area of concern is the treatment of prostate cancer with androgen deprivation, which loses effectiveness after a certain time. The concurrent blocking of the secretion of adrenal C19-steroids, whether using corticoids or adrenostatics, could increase the effectiveness of androgen-deprivation therapy.<\/jats:p>","DOI":"10.33549\/physiolres.934516","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T12:20:50Z","timestamp":1602850850000},"page":"S187-S192","source":"Crossref","is-referenced-by-count":12,"title":["11-Keto-testosterone and Other Androgens of Adrenal Origin"],"prefix":"10.33549","author":[{"given":"L.","family":"ST\u00c1RKA","sequence":"first","affiliation":[{"name":"Institute of Endocrinology, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"DU\u0160KOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"V\u00cdTK\u016e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"AZZIZ R, BLACK V, HINES GA, FOX LM, BOOTS LR: Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 83: 2317-2323, 1998. https:\/\/doi.org\/10.1210\/jc.83.7.2317","DOI":"10.1210\/jc.83.7.2317"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"BARNARD M, QUANSON JL, MOSTAGHEL E, PRETORIUS E, SNOEP, STORBECK KH: 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183: 192-201, 2018. https:\/\/doi.org\/10.1016\/j.jsbmb.2018.06.013","DOI":"10.1016\/j.jsbmb.2018.06.013"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BLOEM LM, STORBECK KH, SCHLOMS L, AMANDA C, SWART AC: 11\u03b2-Hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function. Molecules 18: 13228-13244, 2013. https:\/\/doi.org\/10.3390\/molecules181113228","DOI":"10.3390\/molecules181113228"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"DU\u0160KOV\u00c1 M, KOL\u00c1TOROV\u00c1 L, ST\u00c1RKA L: Androgens in women - critical evaluation of the methods for their determination in diagnostics of endocrine disorders. Physiol Res 67 (Suppl 3): S379-S390, 2018. https:\/\/doi.org\/10.33549\/physiolres.933964","DOI":"10.33549\/physiolres.933964"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"DU TOIT T, SWART AC: Inefficient UGT-conjugation of adrenal 11\u03b2-hydroxyandrostenedione metabolites highlights C11-oxy C19 steroids as the predominant androgens in prostate cancer. Mol Cell Endocrinol 461: 265-276, 2018. https:\/\/doi.org\/10.1016\/j.mce.2017.09.026","DOI":"10.1016\/j.mce.2017.09.026"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"DU TOIT T, SWART AC: The 11\u03b2-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone. J Steroid Biochem Mol Biol 196: 105497, 2020. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105497","DOI":"10.1016\/j.jsbmb.2019.105497"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"IMAMICHI Y, YUHKI KI, ORISAKA M, KITANO T, MUKAI K, USHIKUBI F, TANIGUCHI T, UMEZAWA A, MIYAMOTO K, YAZAWA T: 11-keto-testosterone is a major androgen produced in human gonads. Clin Endocrinol Metab 101: 3582-3591, 2016. https:\/\/doi.org\/10.1210\/jc.2016-2311","DOI":"10.1210\/jc.2016-2311"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"IDLER DR, SCHMIDT PJ, RONALD AP: Isolation and identification of 11-ketotestosterone in salmon plasma. Can J Biochem Physiol 38: 1053-1057, 1960. https:\/\/doi.org\/10.1139\/y60-131","DOI":"10.1139\/y60-131"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"O'REILLY MW, KEMPEGOWDA P, JENKINSON C, TAYLOR AE, QUANSON JL, STORBECK KH, ARLT W: 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. J Clin Endocrinol Metab 102: 840-848, 2017. https:\/\/doi.org\/10.1210\/jc.2016-3285","DOI":"10.1210\/jc.2016-3285"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"OWEN EJ, HOLOWNIA P, CONWAY GS, JACOBS HS, HONOUR JW: 11\u03b2-hydroxyandrostenedione in plasma, follicular fluid, and granulosa cells of women with normal and polycystic ovaries. Fertil Steril 58: 713-718, 1992. https:\/\/doi.org\/10.1016\/S0015-0282(16)55317-5","DOI":"10.1016\/s0015-0282(16)55317-5"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"PRETORIUS E, AFRICANDER DJ, VLOK M, PERKINS MS, QUANSON JL, STORBECK KH: 11-keto-testosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored. PLoS One 11: e0159867, 2016. https:\/\/doi.org\/10.1371\/journal.pone.0159867","DOI":"10.1371\/journal.pone.0159867"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"PUTZ Z, HAMPL R, VELEM\u00cdNSK\u00dd J, KREZE A, \u0160ULCOV\u00c1 J, ST\u00c1RKA L: Radioimmunoassay of 11\u03b2-hydroxyandrostendione in laboratory diagnostics of selected endocrine disorders. J Clin Chem Clin Biochem 25: 723-727, 1987. https:\/\/doi.org\/10.1515\/cclm.1987.25.10.723","DOI":"10.1515\/cclm.1987.25.10.723"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"REGE J, NAKAMURA Y, SATOH F, MORIMOTO R, KENNEDY MR, LAYMAN LC, HONMA S, SASANO H, RAINEY WE: Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J Clin Endocrinol Metab 98: 1182-1188, 2013. https:\/\/doi.org\/10.1210\/jc.2012-2912","DOI":"10.1210\/jc.2012-2912"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"REGE J, TURCU AF, KASA-VUBU JZ, LERARIO AM, AUCHUS GC, AUCHUS RJ, SMITH JM, WHITE PC, RAINEY WE: 11-keto-testosterone is the dominant circulating bioactive androgen during normal and premature adrenarche. J Clin Endocrinol Metab 103: 4589-4598, 2018. https:\/\/doi.org\/10.1210\/jc.2018-00736","DOI":"10.1210\/jc.2018-00736"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"REGE J, GARBER S, CONLEY AJ, ELSEY RM, TURCU AF, AUCHUS RJ, RAINEY WE: Circulating 11-oxygenated androgens across species. J Steroid Biochem Mol Biol 190: 242-249, 2019. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.04.005","DOI":"10.1016\/j.jsbmb.2019.04.005"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"SKIBA MA, BELL RJ, ISLAM RM, HANDELSMAN DJ, DESAI R, DAVIS SR: Androgens during the reproductive years: what is normal for women? J Clin Endocrinol Metab 104: 5382-5392, 2019. https:\/\/doi.org\/10.1210\/jc.2019-01357","DOI":"10.1210\/jc.2019-01357"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"STORBECK KH, BLOEM LM, AFRICANDER D, SCHLOMS L, SWART P, SWART AC: 11\u03b2-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? Mol Cell Endocrinol 377: 135-146, 2013. https:\/\/doi.org\/10.1016\/j.mce.2013.07.006","DOI":"10.1016\/j.mce.2013.07.006"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"STORBECK KH, SCHIFFER L, BARANOWSKI ES, CHORTIS V, PRETE A, BARNARD L, GILLIGAN LC, TAYLOR AE, IDKOWIAK J, ARLT W, SHACKLETON CHL: Steroid metabolome analysis in disorders of adrenal steroid biosynthesis and metabolism. Endocr Rev 40: 1605-1625, 2019. https:\/\/doi.org\/10.1210\/er.2018-00262","DOI":"10.1210\/er.2018-00262"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"SWART AC, SCHLOMS L, STORBECK KH, BLOEM LM, TOIT TD, QUANSON JL, RAINEY WE, SWART P: 11\u03b2-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5\u03b1-reductase yielding 11\u03b2-hydroxy-5\u03b1-androstanedione. J Steroid Biochem Mol Biol 138: 132-142, 2013. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.04.010","DOI":"10.1016\/j.jsbmb.2013.04.010"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"TURCU AF, NANBA AT, CHOMIC R, UPADHYAY SK, GIORDANO TJ, SHIELDS JJ, MERKE DP, RAINEY WE, ANCHUS RJ: Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol 174: 601-609, 2016. https:\/\/doi.org\/10.1530\/EJE-15-1181","DOI":"10.1530\/eje-15-1181"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"TURCU AF, AUCHUS RJ: Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes 24: 252-259, 2017. https:\/\/doi.org\/10.1097\/MED.0000000000000334","DOI":"10.1097\/med.0000000000000334"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"TURCU AF, NANBA AT, AUCHUS RJ: The rise, fall, and resurrection of 11-oxygenated androgens in human physiology and disease. Horm Res Paediatr 89: 284-291, 2018. https:\/\/doi.org\/10.1159\/000486036","DOI":"10.1159\/000486036"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"YOSHIDA T, MATSUZAKI T, MIYADO M, SAITO K, IWASA T, MATSUBARA Y, OGATA T, IRAHARA M, FUKAMI M: 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocrine J 65: 979-990, 2018. https:\/\/doi.org\/10.1507\/endocrj.EJ18-0212","DOI":"10.1507\/endocrj.ej18-0212"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T12:20:53Z","timestamp":1602850853000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2020\/69_S187.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":23,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934516","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}